three
five
trial
use
liposomemedi
gene
transfer
strategi
one
trial
use
one
noon
et
al
transfect
nasal
epithelium
cf
patient
abl
detect
vectorspecif
dna
day
gene
transfer
mrna
function
correct
cftr
defect
discrep
trial
previous
publish
nose
trial
abl
detect
cftr
mrna
partial
correct
cftr
defect
like
due
lower
transfect
effici
cation
lipid
use
doseescal
safeti
trial
liposom
dna
complex
aerosolis
lung
cf
subject
half
transient
fever
muscl
joint
pain
shortli
correspond
u
griesenbach
depart
gene
therapi
faculti
medicin
nation
heart
lung
institut
imperi
colleg
london
uk
cation
liposom
low
like
insuffici
achiev
clinic
benefit
review
clinic
preclin
progress
last
year
briefli
specul
futur
prospect
next
cf
gene
therapi
gene
therapi
liposomedna
administr
attribut
immunolog
respons
liposomedna
complex
similar
result
previous
report
lung
trial
use
liposomedna
formul
interestingli
hyde
et
al
demonstr
first
time
liposomedna
complex
could
success
readminist
nose
cf
patient
subject
receiv
three
dose
administ
week
apart
sampl
analys
day
treatment
six
treat
subject
posit
cftr
gene
transfer
dose
perricon
et
al
report
result
phase
clinic
trial
recombin
adenoviru
administ
bronchoscop
instil
aerosolis
lung
cf
patient
contrast
previou
studi
author
care
determin
ineffici
gene
express
due
low
transduct
effici
ad
human
airway
addit
vast
major
transfect
cell
appear
epitheli
cell
author
therefor
conclud
improv
ad
vector
design
urgent
requir
vector
nebulis
lung
cf
subject
assess
deliveri
safeti
administr
lung
appear
safe
vector
genom
detect
highest
dose
day
administr
howev
vectorspecif
mrna
could
detect
therefor
evid
gene
transfer
provid
summari
new
studi
consolid
view
proofofprincipl
gene
transfer
demonstr
studi
gene
transfer
efficaci
current
insuffici
warrant
phase
iiiii
trial
thu
signific
improv
aspect
gene
transfer
need
made
encourag
progress
made
overcom
extracellular
barrier
airway
gene
transfer
mucu
glycocalyx
major
function
airway
epithelium
prevent
uptak
foreign
materi
includ
gene
transfer
agent
gta
purpos
sever
effect
extracellular
barrier
mucu
gycocalyx
tight
junction
mucociliari
clearanc
evolv
figur
mucu
exampl
reduc
transfect
effici
viral
nonvir
gene
transfer
agent
howev
transfect
effici
could
increas
pretreat
mucolyt
antichiolinerg
drug
glycopyrol
vitro
vivo
addit
mucu
sputum
bronchoalveolar
lavag
fluid
recov
cf
patient
shown
inhibit
liposom
adenoviru
aavmedi
gene
transfer
effici
although
recombin
dnase
reduc
sputum
viscoelast
improv
nanospher
migrat
vitro
effect
dnase
gene
transfer
vivo
unclear
avoid
confound
effect
sputum
vivo
gene
transfer
ideal
studi
cf
children
lung
becom
fill
secret
indirect
evid
indic
glycocalyx
also
barrier
gene
transfer
neu
gene
therapi
roaminidas
enhanc
ad
transfect
polaris
cell
vitro
receptor
ad
locat
basolater
membran
human
airway
epitheli
cell
uptak
nonvir
gene
transfer
agent
also
appear
enhanc
basolater
site
due
presenc
heparan
receptor
higher
endocytosi
rate
effect
sever
tight
junction
open
includ
egta
antiecadherin
antibodi
sodium
caprat
blend
sucros
mannitol
pluron
perfluorochem
gene
transfer
studi
vitro
vivo
although
increas
virusand
nonvirusmedi
gene
transfer
gener
seen
vitro
unlik
open
tight
junction
even
transient
clinic
applic
given
airway
cf
patient
heavili
colonis
bacteria
summari
although
encourag
progress
made
partial
overcom
extracellular
barrier
unlik
strategi
significantli
improv
gene
transfer
human
airway
howev
may
prove
benefici
combin
strategi
see
liposom
synthet
vector
also
unabl
transfect
airway
epitheli
cell
effici
via
apic
membran
target
receptormedi
endocytosi
may
increas
gene
transfer
proofofprincipl
approach
recent
provid
ziadi
et
al
shown
target
serpin
enzym
complex
receptor
secr
increas
gene
transfer
nasal
epithelium
mice
secr
ligand
link
cftr
plasmid
via
polyllysin
bridg
formul
partial
correct
cftr
defect
chlorid
efflux
nose
cftr
knockout
mice
remark
demonstr
first
time
vivo
cfrelat
secondari
defect
nitric
oxid
sodium
hyperabsorpt
partial
correct
gene
therapi
well
target
secr
success
increas
airway
gene
transfer
sever
group
current
tri
identifi
new
peptid
bind
airway
epitheli
cell
promot
target
receptormedi
endocytosi
use
phage
display
librari
mention
densiti
receptor
ad
apic
membran
human
airway
epitheli
cell
low
explain
part
ineffici
transfect
effici
multipl
approach
studi
overcom
problem
firstli
sever
new
recombin
virus
identifi
appear
abl
enter
epitheli
cell
via
apic
membran
effici
addit
respiratori
syncyti
viru
rsv
sendai
viru
sev
recent
shown
transfect
bronchial
epitheli
cell
effici
vivo
two
day
infect
sev
airway
epitheli
cell
express
transgen
figur
sev
use
bind
cholesterol
sialic
acid
receptor
present
apic
membran
airway
epitheli
cell
addit
sev
greatli
inhibit
mucu
aav
entri
airway
epitheli
cell
appear
serotypespecif
shown
transfect
airway
epitheli
cell
five
time
effici
aav
gener
promis
gene
transfer
agent
viru
maintain
prolong
transgen
express
due
integr
concatemeris
vector
genom
also
thought
viru
might
less
immunogen
due
fact
appear
transduc
antigenpres
dendrit
cell
report
suggest
aav
could
repeatedli
administ
lung
howev
possibl
recent
rule
unless
differ
serotyp
form
immunosuppress
use
import
limit
aav
gene
transfer
vector
cf
limit
packag
capac
howev
recent
demonstr
problem
overcom
use
transsplic
overlap
vector
shorten
cftr
cdna
secondli
proofofprincipl
establish
adeno
aav
vector
retarget
apic
surfac
receptor
bradykinin
urokinas
plasminigen
purinoreceptor
vitro
howev
remain
establish
approach
increas
transfect
effici
vivo
third
strategi
involv
systemat
pseudotyp
envelop
viru
differ
envelop
glycoprotein
glycoprotein
virus
natur
infect
airway
epitheli
cell
human
coronaviru
influenza
strain
member
filoviru
famili
marburg
ebola
viru
good
candid
pseudotyp
lentivir
vector
human
felin
equin
immunodefici
viru
particularli
attract
approach
lentivir
vector
abil
integr
genom
divid
nondivid
differenti
cell
express
therefor
prolong
compar
episom
maintain
vector
may
last
forev
integr
stem
cell
occur
pseudotyp
hiv
vector
effici
transfect
airway
epitheli
cell
vivo
interestingli
express
low
day
administr
strong
express
visibl
airway
epithelium
submucos
gland
cell
day
transfect
tracheal
epithelium
express
persist
least
day
tracheal
epithelium
express
report
gene
figur
current
largescal
high
titr
product
pseudotyp
lentivir
vector
technic
difficult
critic
limit
factor
identif
virus
capabl
effici
transfect
airway
epithelium
via
apic
membran
one
excit
find
last
year
although
big
problem
repeat
administr
still
exist
proofofprincipl
studi
demonstr
primari
cftr
defect
consist
correct
human
becom
possibl
transgen
express
remain
transient
unless
lung
repopul
stem
cell
target
stabli
maintain
vector
treatment
cf
gene
therapi
therefor
requir
repeat
administr
gene
transfer
agent
particular
problem
virus
strategi
administr
immunosuppress
corticosteroid
treatment
aim
transient
block
cell
evalu
repeat
administr
adenoviru
howev
success
strategi
limit
gener
repeat
administr
possibl
time
ultim
lead
reduc
final
absent
transgen
express
except
far
report
kolb
et
al
demonstr
administr
steroid
budesonid
enabl
adenoviru
readminist
least
five
time
without
loss
transfect
effici
importantli
treatment
ligand
monoclon
antibodi
prevent
viru
specif
antibodi
respons
nonhuman
primat
anoth
perhap
promis
approach
base
gener
stealth
viru
invis
immun
system
coat
viru
capsid
polyethylen
glycol
peg
pegyl
viru
capsid
reduc
cytotox
cell
antibodi
product
significantli
prolong
transgen
express
day
repeat
administr
adenoviru
modifi
peg
success
howev
differ
peg
formul
use
signific
transgen
express
detect
repeat
administr
although
demonstr
repeat
administr
liposomedna
complex
nose
cf
patient
possibl
concern
rais
regard
inflammatori
compon
bacteri
dna
abund
unmethyl
cpg
motif
bacteri
plasmid
dna
may
least
part
respons
inflammatori
respons
sever
strategi
current
explor
decreas
unwant
properti
methyl
cpg
sequenc
reduct
cpg
frequenc
elimin
nonessenti
region
sitedirect
mutagenesi
use
specif
inhibitor
cpg
signal
pathway
chloroquin
quinacrin
summari
progress
enabl
repeat
administr
virus
rather
slow
concern
regard
viral
nonvir
gtainduc
inflamm
rais
detail
understand
immun
respons
viral
nonvir
gta
therefor
crucial
improv
gene
transfer
intracellular
barrier
limit
transgen
express
also
identifi
endosom
cytoplasm
degrad
particular
problem
nonvir
gene
transfer
agent
cytoplasm
ca
sensit
cytosol
nucleas
restrict
halflif
plasmid
dna
min
interestingli
even
recombin
virus
inhibit
intracellular
degrad
polaris
cell
aav
capsid
ubiquin
subsequ
enter
ubiquitin
proteasomedepend
degrad
pathway
thu
proteasom
inhibitor
augment
gene
transfer
mous
lung
undetect
level
airway
epitheli
cell
transfect
airway
epitheli
cell
nuclear
membran
import
barrier
nonvir
gene
transfer
current
uncertain
strategi
addit
nuclear
localis
signal
lactosyl
polyllysin
increas
nuclear
transfect
cell
type
benefici
although
demonstr
aav
degrad
proteasom
nonvir
gta
probabl
affect
intracellular
degrad
nuclear
entri
virus
thu
new
strategi
urgent
requir
overcom
intracellular
barrier
also
import
note
barrier
like
celltyp
specif
therefor
studi
need
carri
relev
cell
type
current
nonintegr
viral
nonvir
gta
unabl
maintain
sustain
express
immunosuppress
report
prolong
transgen
express
due
abil
reduc
cellmedi
respons
addit
scaria
et
al
show
incorpor
adenovir
gene
adenovir
vector
reduc
mhc
class
antigen
present
cell
prolong
express
primat
lung
day
strong
cmv
promot
tradit
use
gta
howev
recent
evid
provid
weaker
eukaryot
hybrid
promot
polyubiquitin
c
promot
elong
factor
promot
cmvubiquitin
b
hybrid
promot
enabl
prolong
transgen
express
addit
grow
evid
genom
sequenc
either
within
flank
gene
might
essenti
provid
vivo
longterm
express
altern
strategi
prolong
transgen
express
includ
develop
artifici
chromosom
selfrepl
system
huerta
et
al
develop
circular
yeast
artifici
chromosom
yac
carri
human
cftr
sequenc
orip
gene
epsteinbarr
ebv
viru
howev
remain
establish
larg
construct
abl
transfect
airway
epitheli
cell
vivo
note
topic
gene
transfer
lung
sever
affect
mani
extracellular
barrier
attempt
overcom
barrier
gta
oligonucleotid
odn
administ
intraven
iv
like
iv
administ
gta
reach
bronchial
circul
avoid
lodg
pulmonari
circul
reach
relev
target
cell
cf
therapi
fox
et
al
recent
demonstr
nake
odn
abl
leav
bronchial
circul
transfect
cytoplasm
nuclei
airway
epitheli
cell
addit
kohler
et
al
shown
iv
inject
lipidcomplex
plasmid
lead
express
bronchial
epithelium
tracheal
submucos
gland
mice
howev
achiev
cation
lipid
test
importantli
past
sometim
difficult
discrimin
recombin
endogen
express
therefor
import
potenti
excit
find
expand
upon
possibl
utero
gene
therapi
cf
also
investig
inject
gta
amniot
fluid
would
provid
contact
relev
target
site
cf
pulmonari
gastrointestin
sinu
epithelium
inject
adenoviru
retroviru
recent
aav
result
report
gene
express
pulmonari
gastrointestin
epithelium
persist
transgen
express
lung
rang
day
infect
possibl
utero
gene
therapi
would
toleris
recipi
viral
gta
recent
rule
genom
gene
repair
mrna
transsplic
antisens
approach
introduc
cf
gene
repair
endogen
cftr
gene
two
major
advantag
tradit
gene
therapi
success
gene
repair
ensur
gene
express
lifetim
cell
appropri
control
gene
express
guarante
endogen
cftr
promot
utilis
preliminari
result
indic
genom
cftr
locu
could
modifi
primari
rat
hepatocyt
use
chimeraplast
dnarna
hybrid
oligonucleotid
hepatocyt
previous
shown
easili
amen
gene
repair
strategi
like
due
effici
uptak
repair
molecul
nucleu
addit
similar
approach
use
small
fragment
homolog
recombin
sfhr
abl
reintroduc
wildtyp
cftr
sequenc
lung
cf
knockout
mice
albeit
low
frequenc
howev
specif
target
gene
repair
current
unknown
downregul
gene
express
antisens
molecul
may
therapeut
benefit
cf
lambert
et
al
show
antisens
inhibit
b
cell
antigen
receptorassoci
protein
bap
increas
express
wildtyp
cftr
mutant
cftr
partial
restor
cftr
chlorid
channel
function
exact
function
unclear
although
author
specul
protein
may
involv
retain
mutant
cftr
er
sever
chaperon
protein
mucin
epitheli
sodium
channel
enac
upregul
cf
may
suitabl
candid
antisens
strategi
spliceosomemedi
transsplic
smart
recent
introduc
mean
gener
wildtyp
cftr
mrna
cf
xenograft
model
cell
transfect
high
titr
adenoviru
produc
socal
pretherapeut
wildtyp
cftr
mrna
molecul
ptm
design
promot
transsplic
endogen
cftr
mrna
wildtyp
cftr
function
could
restor
similar
gene
repair
smart
ensur
celltyp
specif
express
wildtyp
cftr
mrna
howev
effici
specif
reaction
requir
improv
clinic
trial
consid
togeth
tradit
gta
new
approach
develop
order
increas
gene
transfer
effici
airway
epithelium
gerst
et
al
recent
report
applic
magnet
field
human
primari
airway
epitheli
cell
transfect
plasmid
dna
mix
superparamagnet
nanoparticl
magnetofect
result
increas
gene
transfer
stem
cellbas
gene
therapi
approach
also
investig
two
strategi
envisag
either
target
lungresid
stem
cell
integr
vector
engin
bone
marrowembryon
cell
ex
vivo
induc
engraft
airway
epithelium
thu
bone
marrowderiv
stem
cell
recent
observ
diferenti
airway
epitheli
cell
lung
prolong
sustain
cftr
express
may
benefici
especi
integr
vector
use
end
epitheliumspecif
regul
cassett
develop
vector
technolog
test
relev
vivo
model
ideal
contrast
cf
mice
would
reproduc
lung
patholog
seen
cf
patient
reason
effort
made
develop
cf
ferret
cf
sheep
lung
biolog
similar
human
mous
final
new
imag
techniqu
monitor
effici
gene
transfer
live
animalspati
also
develop
addit
positron
emiss
tomographi
pet
magnet
reson
imag
mri
base
strategi
laserinduc
fluoresc
bronchoscopi
recent
develop
way
detect
gene
express
noninvas
way
human
airway
although
topic
gene
transfer
airway
cf
gene
therapi
challeng
origin
thought
signific
progress
made
preclin
research
last
year
overcom
hurdl
importantli
identif
effect
viral
nonvir
gene
transfer
agent
airway
gene
deliveri
develop
new
deliveri
rout
recent
altern
strategi
keep
develop
cf
gene
therapi
well
track
